Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $197.84 USD
Change Today -0.62 / -0.31%
Volume 1.0M
VRX On Other Exchanges
As of 8:04 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Robert Roswell Chai-Onn

Chief Legal Officer, Head of Corporate & Business Development, Executive Vice President, General Counsel and Corporate Secretary, Valeant Pharmaceuticals International, Inc.
AgeTotal Calculated CompensationThis person is connected to 12 board members in 4 different organizations across 6 different industries.

See Board Relationships
As of Fiscal Year 2013


Mr. Robert Roswell Chai-Onn has been Secretary of Solta Medical, Inc. since January 23, 2014. Mr. Chai-Onn has been Head of Corporate & Business Development and Chief Legal Officer at Valeant Pharmaceuticals International, Inc. since January 10, 2014 and has been its Executive Vice President, General Counsel and Corporate Secretary since September 2010. He served as an Executive Vice President of Corporate Business Development at Valeant Pharmaceuticals International, ...

Read Full Background

Corporate Headquarters*

2150 St. Elzéar boulevard West
Laval, Quebec H7L 4A8


Phone: 514-744-6792
Fax: 514-744-6272

Board Members Memberships*

Executive Officer and Director
Secretary and Director
Secretary and Director


Bachelor's Degree
Yale University
Master's Degree
University of Cambridge
School Of Law, Columbia University

Other Affiliations*

Annual Compensation*

Total Annual Compensation$750,000

Stock Options*

Restricted Stock Awards$568,717
All Other Compensation$6,765
Exercisable Options315,107
Exercisable Options Value$32,077,946
Unexercisable Options241,745
Unexercisable Options Value$7,841,335
Total Value of Options$39,919,280
Total Number of Options556,852

Total Compensation*

Total Annual Cash Compensation$2,101,609
Total Short Term Compensation$750,000
Other Long Term Compensation$575,482
Total Calculated Compensation$12,021,326
*Data is at least as current as the most recent Definitive Proxy.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VRX:US $197.84 USD -0.62


Dilip Shantilal Shanghvi Managing Director, Executive Director and Member of Shareholders/Investors Grievance Committee
Sun Pharmaceutical Industries Limited
Heather Bresch Chief Executive Officer, Executive Director and Member of Science & Technology Committee
Mylan N.V.
Erez Vigodman Chief Executive Officer, President, Director and Member of Finance & Invesment Committee
Teva Pharmaceutical Industries Limited
Haruo Naito Chief Executive Officer, Representative Corporate Officer and Director
Eisai Co., Ltd.
Yoshihiko Hatanaka Chief Executive Officer, President and Representative Director
Astellas Pharma, Inc.
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VALEANT PHARMACEUTICALS INTE, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at